Brolucizumab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized |
| Target | Vascular endothelial growth factor A (VEGFA) |
| Clinical data | |
| Trade names | Beovu |
| Other names | brolucizumab-dbll, RTH258, DLX1008 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620001 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravitreal |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1164H1768N310O372S7 |
| Molar mass | 26281.17 g·mol−1 |
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye).
Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.